Skip to content

Getting Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) To The UK Continues (October 24, 2012 Update)

October 24, 2012

       The Cystic Fibrosis (CF) Trust in the UK issues a statement on October 24, 2012, with an update on the Clinical Priorities Advisory Group (CPAG) meeting held on Monday, October 22, 2012.  The purpose of this meeting was to discuss the cost effectiveness of providing Vertex Pharmaceuticals’ orphan drug Kalydeco to UK patients. Here is the latest status :

  1.  Final recommendations regarding cost-effectiveness have not yet been agreed upon
  2. CPAG asks for additional analysis that is to be made available within 2 weeks to meet the timetable for submitting final recommendations to the 4 SCGs
  3. 4 SCGs’ December 2012 board meetings.

References 

CF Trust UK “Campaign for Kalydeco” ePetition  

Clinical Priorities Advisory Group (CPAG) October 24, 2012 Statement  

Vertex Pharmaceuticals Statement  

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: